Ikewaki Nobunao, Iwasaki Masaru, Abraham Samuel J K
Department of Medical Life Science, Kyushu University of Health and Welfare, Nobeoka, Japan.
Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki Japan.
J Diabetes Metab Disord. 2020 Oct 21;19(2):2041-2044. doi: 10.1007/s40200-020-00664-4. eCollection 2020 Dec.
With the COVID-19 pandemic causing huge threat to public health and definite treatment modalities and preventive vaccines yet to be arrived at, some of the key indicators of relevance to its prognosis have started emerging. One such independent predictor of outcome has been fasting plasma glucose (FPG) at the time of admission. Earlier, co-morbidities such as diabetes also have been reported to have a risk of relatively increased mortality due to COVID-19. In this background, we herein report on the beneficial effects of Biological response modifier glucan (BRMG) secreted by the black yeast AFO-202 which has been proven to bring under control blood sugar levels in human subjects and also has potential in enhancing & regulating the immune parameters in relevance to COVID-19. We further recommend that this BRMG be tried in clinical studies of COVID-19 to provide a prophylactic effect for validation.
随着新冠疫情对公众健康构成巨大威胁,且明确的治疗方式和预防性疫苗尚未出现,一些与其预后相关的关键指标已开始显现。其中一个独立的预后预测指标是入院时的空腹血糖(FPG)。此前,也有报道称糖尿病等合并症会因新冠病毒而导致死亡率相对增加。在此背景下,我们在此报告黑酵母AFO - 202分泌的生物反应调节剂葡聚糖(BRMG)的有益作用,该调节剂已被证明能控制人体血糖水平,并且在增强和调节与新冠病毒相关的免疫参数方面具有潜力。我们进一步建议在新冠病毒的临床研究中试用这种BRMG,以验证其预防效果。